Morgan Stanley lowered the firm’s price target on Atea Pharmaceuticals (AVIR) to $6 from $6.20 and keeps an Equal Weight rating on the shares. Following year-end earnings, the firm rolled forward the discount period it applies and tweaked its R&D and SG&A estimates to align with trends, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVIR:
- Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study
- Atea Pharmaceuticals cuts 25% of workforce, exploring partnerships
- Radoff-JEC Group nominates candidates to Atea Pharmaceuticals board
- Atea Pharmaceuticals issues statement regarding director nominations
- Atea Pharmaceuticals announces presentation of bemnifosbuvir preclinical data